Jonathan Aschoff

Michael Okunewitch

Elemer Piros

Jason McCarthy

- BioRestorative Therapies, Inc. announced a **$1.085 million registered direct offering** of common stock and a concurrent private placement of unregistered warrants.  **[1505497_0001493152-25-017446_ex99-1.htm:0]** **[1505497_0001493152-25-017446_form8-k.htm:1]** 
- The offering includes the sale of **678,125 shares of common stock at $1.60 per share**, priced above the market close of $1.50 on October 3, 2025.  **[1505497_0001493152-25-017446_ex99-1.htm:0]** **[1505497_0001493152-25-017446_form8-k.htm:1]** 
- Concurrently, the company will issue **unregistered warrants to purchase up to 508,594 shares** of common stock, with an **exercise price of $2.75 per share**.  **[1505497_0001493152-25-017446_ex4-1.htm:0]** **[1505497_0001493152-25-017446_ex99-1.htm:0]** **[1505497_0001493152-25-017446_form8-k.htm:1]** 
- The net proceeds from the offering are intended to fund **clinical trials for BRTX-100, pre-clinical research and development for its ThermoStem® Program, development of its biocosmeceuticals platform, and general corporate purposes**.  **[1505497_0001493152-25-017446_ex99-1.htm:0]** **[1505497_0001493152-25-017446_form8-k.htm:1]** 
- The closing of the offering is expected on or about **October 8, 2025**.  **[1505497_0001493152-25-017446_ex99-1.htm:0]** **[1505497_0001493152-25-017446_form8-k.htm:1]**

BioRestorative Therapies (BRTX)